CRRUA: 1 arsenic plant ‘slightly' above guidelines
The Environmental Protection Agency's maximum contaminate level (MCL) for arsenic is 10 parts per billion (ppb).
Test results, released by Eurofins Environment Testing, an independent water lab certified by the New Mexico Environment Department (NMED), showed the Sunland Park ATF at 6.2 ppb, the Santa Teresa Community ATF at 4.5 ppb and the Santa Teresa Industrial ATF at 12 ppb, the utility said.
'When we received the test results for the Santa Teresa Industrial ATF, we immediately implemented protocols and standard operating procedures (SOPs) we initiated in partnership with NMED, and adjusted treatment that lowered the arsenic level to below the MCL,' CRRUA Executive Director Juan Crosby said. 'At no time was the public health at risk. The water continues to meet NMED and EPA standards and is safe to consume.'
Crosby said CRRUA also notified NMED about the test results, in accordance with standard operating procedures.
Crosby said CRRUA will continue to conduct daily monitoring at all ATFs and will follow up with additional testing at the Santa Teresa Industrial ATF on May 13 and May 20, utilizing an independent, NMED-certified laboratory.
Crosby said developing standard operating procedures was a priority when he was named CRRUA acting executive director in January 2024.
'Our quick response in correcting the exceedance at the Santa Teresa Industrial ATF is a direct result of the processes we enacted. I am extremely proud of the timely and proper corrective actions our team took to protect the health and safety of CRRUA customers,' Crosby said.
Crosby said the voluntary monthly testing CRRUA has been conducting since February 2024 is to not only for internal monitoring purposes, but for public transparency.
'Our monthly testing is strictly voluntary,' Crosby said. 'It is a proactive process we undertake to keep our customers constantly informed about water quality. We post arsenic test results on the CRRUA website at crrua.org and on the CRRUA Facebook page.'
He said although the tests are conducted by an independent, NMED-certified lab, they are not for compliance purposes. Only the quarterly tests NMED conducts are for compliance, he said to explain the process further.
CRRUA excluded the Border Entry ATF from its voluntary testing due to its continued meeting of federal and state requirements.
The water samples used in the most recent testing were collected on April 23.
As of January 2025, all four arsenic treatment facilities (ATFs) operated by CRRUA are NMED compliant, which means they were below EPA's MCL for four consecutive quarters, the utility said.
So far this year, CRRUA passed NMED's first quarter arsenic test, and three-monthly voluntary tests verified by an independent laboratory.
Since Jan. 24, 2024, CRRUA has passed 22 arsenic tests including four quarterly NMED tests, the utility said.
Arsenic tests results are available on the CRRUA website at crrua.org.
CRRUA said it recently achieved 94.8% compliance in correcting deficiencies identified by NMED in its 2023 survey of the utility. Of the 58 deficiencies identified, CRRUA has corrected 55, the utility said.
CRRUA provides water and wastewater services to Sunland Park and Santa Teresa.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
17 hours ago
- Business Upturn
Mellow Sleep Redefines Comfort with a Revolutionary New Cloud Pillow
Dover, Aug. 12, 2025 (GLOBE NEWSWIRE) — DOVER, DE – August 11, 2025 – Mellow Sleep, a leader in sleep ergonomics and material science, today announced the launch of a revolutionary new cloud pillow designed to permanently solve the universal problem of restless, unfulfilling sleep. This launch marks a new era for sleep wellness, moving beyond one-size-fits-all solutions to offer a truly personalized and restorative experience. The frustrating, nightly search for a pillow that is 'just right' is finally over. Millions of people struggle with pillows that are too firm, too soft, too high, or too low, leading to neck pain, shoulder stiffness, and persistent fatigue. This nightly battle for comfort often involves folding, bunching, or stacking pillows in a desperate attempt to find support. Mellow Sleep addresses this issue at its core with a groundbreaking cloud pillow that intelligently adapts to the sleeper. This innovative pillow solves sleep discomfort through its proprietary 3-zone contour design. Each zone is meticulously engineered for a distinct biomechanical purpose. The central contour cradles the head with gentle, pressure-relieving support, while the raised outer edges are optimized for side sleepers, filling the gap between the shoulder and neck. The third zone provides a specialized cervical ramp that delivers a targeted lift, ensuring the spine maintains a natural and healthy alignment throughout the night. This integrated system prevents the awkward angles that lead to morning aches and pains. 'Our goal was to create the perfect cloud pillow by listening to the real-world frustrations of sleepers,' said Jay Yue, founder of Mellow Sleep. 'People are tired of compromising. They shouldn't have to choose between a soft feel and firm support. We spent years researching materials and ergonomics to find a way to deliver both. The result is our new CloudAlign™ Pillow, a product we believe sets a new industry standard for what a pillow can and should do for your well-being. It's more than just a place to rest your head; it's an investment in your health.' At the heart of this exceptional Mellow Sleep cloud pillow is the CloudSoft Core™, a proprietary shape-retaining memory foam. Unlike conventional foams that can be slow to respond or lose shape, the CloudSoft Core™ offers dynamic, flexible support that adapts instantly to every micro-movement. This ensures consistent comfort and alignment, whether you are a back, side, or combination sleeper. The exterior is just as thoughtfully designed. The pillow is encased in a removable, OEKO-TEX® Certified cover. This certification guarantees the fabric is free from harmful chemicals, making it hypoallergenic, breathable, and exceptionally gentle on the skin. Further enhancing its superior adaptability, the pillow features a SwitchFit™ design. This innovative feature gives users dual-height support, allowing them to simply flip the pillow to choose between a lower and a higher profile to perfectly match their body frame and sleep preference. For lasting hygiene, all materials are fast-drying and easily washable. This new Mellow Sleep cloud pillow from Mellow Sleep is now available for purchase directly from the company's website: offering an end to compromise and a new beginning for deep, restorative sleep. About Mellow Sleep: Mellow Sleep is a forward-thinking company dedicated to advancing human well-being through the science of sleep. By focusing on biomechanics, certified non-toxic materials, and user-centric design, Mellow Sleep creates innovative products that provide tangible improvements to sleep health. Their mission is to engineer a better night's sleep for a better life. Media Contact: [email protected] ### For more information about Mellow LLC, contact the company here: Mellow LLCJay Yue9293555134 [email protected] 8 The Green, Dover, DE 19901
Business Wire
20 hours ago
- Business Wire
Navitus Health Solutions Earns 2025-2026 Great Place To Work Certification™
MADISON, Wis.--(BUSINESS WIRE)-- Navitus Health Solutions announced today it has been Certified™ by Great Place To Work ®. The prestigious award is based entirely on what current associates say about their experience working at the company. This year, 85% of associates said it's a great place to work – more than 25 points higher than the average U.S. company. Associates recognized the company's culture as welcoming and engaging, with remarkable opportunities for professional growth. 'Navitus Health Solutions strives to be a preferred employer. We recruit and retain top talent, incorporate equitable representation at every level of the organization, and implement effective learning and development opportunities,' said David Fields, President and CEO, Navitus Health Solutions. 'We're proud to become Great Place To Work-Certified™, a recognition that reflects our ongoing commitment to cultivating a culture rooted in purpose, passion and putting people first.' Great Place To Work ® is the global authority on workplace culture, associate experience, and leadership behaviors proven to deliver market-leading revenue, associate retention and increased innovation. "Great Place To Work Certification is a highly coveted achievement that requires consistent and intentional dedication to the overall associate experience," says Sarah Lewis-Kulin, the Vice President of Global Recognition at Great Place To Work. She emphasizes that Certification is the sole official recognition earned by the real-time feedback of associates regarding their company culture. 'By successfully earning this recognition, it is evident that Navitus Health Solutions stands out as one of the top companies to work for, providing a great workplace environment for its associates." For more than 20 years, Navitus Health Solutions has been an innovator in removing cost from the drug supply chain, first as a 100% transparent, pass-through PBM and then through its specialty pharmacy and medical specialty management capabilities. With the ongoing need for greater accessibility and medication affordability, the company continues to advance its mission on behalf of its various stakeholders. As an employer, Navitus Health Solutions is committed to creating an environment where associates can advance their careers and develop into future leaders within the company. The culture reflects an unwavering commitment to innovation, collaboration and doing what's right to make a positive impact on the lives of its members and in the communities it serves. 'Every associate understands how their work contributes to something larger than themselves. This clarity of mission creates alignment, engagement and a deep sense of meaning,' said David Simmons, Chief People & Culture Officer. 'We continue to focus on and fuel a work environment focused on community, recognition, communication, mentorship and continued career growth.' To learn more about working at Navitus Health Solutions, please visit: About Navitus Health Solutions Navitus Health Solutions is a pioneering pharmacy solutions provider that first launched a transparent pharmacy benefit manager (PBM) to pass through 100% of negotiated drug rebates and discounts to health plans and plan sponsors. The Navitus PBM is an alternative to traditional PBMs which divert rebates and discounts for profit. It leads the way in driving meaningful cost savings to help make medications more affordable. More than 20 years after its founding, the Navitus Health Solutions organization delivers a range of services through portfolio brands including Navitus, Lumicera and Archimedes. Owned by SSM Health and Costco Wholesale Corporation, the company serves over 18 million members across 800 clients, including public and private sector employers, unions, health plans and health systems. For more information, please visit
Business Wire
a day ago
- Business Wire
BostonGene Publishes Landmark Study Providing Clinical and Analytical Validation for Its Multimodal RNA and DNA Assay
WALTHAM, Mass.--(BUSINESS WIRE)-- BostonGene, a leader in AI-powered solutions for drug discovery and development, today announced the publication of a pivotal study, ' Clinical and analytical validation of a combined RNA and DNA exome assay across a large tumor cohort, ' in Communications Medicine, a high-impact journal in the Nature portfolio. The study underscores the BostonGene Tumor Portrait™ assay as a clinically robust, regulatory-grade platform that forms the foundation of BostonGene's AI-powered platform, purpose-built for precision oncology and designed to accelerate therapeutic development and enhance clinical data collection. 'Delivering clinically validated multimodal data from a single tumor sample—and interpreting it through an immune-focused, AI-enabled lens—represents a transformative advancement for oncology drug development.' The Tumor Portrait™ assay integrates DNA and RNA sequencing into a single end-to-end test, delivering a multimodal view of each tumor. Approved under CLIA, CAP and the New York State Department of Health, the platform enhances patient stratification, predictive biomarker discovery and clinical trial enrollment—all critical to reducing the risks associated with drug development and improving clinical trial success rates. The study details the implementation of highly stable clinical RNA-seq protocol, deployed in ready-to-use clinical settings and tested across more than 2,200 tumors, demonstrating high reproducibility, strong clinical actionability (98% of cases) and advanced detection of alterations, fusions, immune signatures, tumor microenvironment profiles and AI-based predictive classifications. 'Delivering clinically validated multimodal data from a single tumor sample—and interpreting it through an immune-focused, AI-enabled lens—represents a transformative advancement for oncology drug development,' said Alexander Bagaev, PhD, Chief Product Officer at BostonGene. 'By combining DNA and RNA sequencing in one assay, our platform enables deeper biological understanding of the tumor microenvironment and genetics, smarter patient selection and more confident, data-driven decisions throughout the drug development lifecycle. This validation sets a new benchmark for translational research and diagnostic innovation.' About BostonGene Corporation BostonGene helps drug developers de-risk and accelerate research and development using a clinically validated AI platform purpose-built for oncology and supported by a CLIA-certified and CAP-accredited clinical laboratory. By integrating advanced molecular and immune profiling with clinical data, we uncover actionable insights that inform trial design, optimize patient selection and improve clinical outcomes. Our diagnostic and treatment recommendation solutions are used in clinical settings to personalize care and guide therapy decisions for patients. For more information, visit
